FDA approves Janssen’s TECVAYLI for multiple myeloma treatment
The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration's approval of its first bispecific T-cell engager antibody, ... Read More
Janssen Covid‑19 vaccine gets conditional marketing authorization in EU
The European Commission has granted a conditional marketing authorization (CMA) for the single dose Janssen Covid‑19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson ... Read More
J&J Ad26.COV2.S COVID-19 vaccine gets FDA emergency use authorization
Johnson & Johnson (J&J) said that the US Food and Drug Administration (FDA) has given emergency use authorization (EUA) for Ad26.COV2.S, a single-dose COVID-19 vaccine ... Read More
Janssen Pharmaceutical’s DARZALEX FASPRO gains FDA approval for AL amyloidosis treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), marking a major milestone in the treatment ... Read More
Janssen acquires HMR59 from Hemera for geographic atrophy treatment
Janssen Pharmaceuticals has secured the rights to an innovative gene therapy, HMR59, for the treatment of geographic atrophy, a severe form of age-related macular degeneration ... Read More
Janssen seeks EMA’s expanded approval for DARZALEX in AL amyloidosis
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) seeking the expanded approval ... Read More
J&J begins phase 3 ENSEMBLE Covid-19 vaccine trial for JNJ-78436735
ENSEMBLE Covid-19 vaccine trial : Johnson & Johnson (J&J) has launched a multi-nation phase 3 trial called ENSEMBLE for its JNJ-78436735 Covid-19 vaccine candidate (Ad26.COV2.S), ... Read More
Janssen, Amgen secure FDA approval for DKd regiment in multiple myeloma
DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have been granted an expanded approval from the ... Read More
Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J
J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech ... Read More
Janssen Covid-19 vaccine candidate Ad26.COV2.S bags $1bn deal from US govt
Johnson & Johnson (J&J) said that its subsidiary Janssen Pharmaceutical has agreed to manufacture and supply 100 million doses of its SARS-CoV-2 investigational vaccine Ad26.COV2.S ... Read More